Himuka AM Pharma Corp.


Drug discovery that contributes to the elimination of Unmet Medical Needs through research and development of drug discovery seeds of adrenomedullin (AM)

AM discovered at Miyazaki University School of Medicine has been suggested to be effective in intractable diseases such as ulcerative colitis and Crohn's disease. By further improving the AM, we are proceeding with the development as a more durable drug. The effect of improved AM has been confirmed in animal experiments, and preparations for administration to humans are currently underway. In addition, clinical research is progressing with expectations for its application in diseases such as cerebral infarction and suppression of the aggravation of pneumonia caused by COVID-19.

Establishment Date
February 2017
Research and development of new drug discovery seeds for improved adrenomedullin
Representative Director Yuji Shinshiro

Point of KII view

As a company that applies AM, which is a bioactive substance found in Japan, to various disease areas, I hope that it will be commercialized.

KII growth support

Introducing candidates for financing and supporting the selection of candidates for business alliances